Pfizer Breakthrough Growth Initiative
Signal active
Investment Firm
Overview
The Pfizer Breakthrough Growth Initiative will focus on making non-controlling equity investments in clinical-stage public companies, with a primary focus on companies with small- to medium-sized market capitalizations across a range of therapeutic categories that are consistent with Pfizer’s core areas of focus: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines and Hospital.
Highlights
Founded
2020
Industry
Employees
0
Investment
9
Lead Investment
8
Exits
6
Stages
Early Stage Venture
Investor Type
Venture Capital
Location
N/A
Contact Information
Social
N/A
Profile Resume
Pfizer Breakthrough Growth Initiative, established in 2020., specializes in Early Stage Venture investments across Biotechnology, Pharmaceutical, Therapeutics, Venture Capital, Finance, Health Care, Medical, Precision Medicine, Financial Services, Business Development. The organization boasts a portfolio of 9 investments, with an average round size of $41.2M and 6 successful exits. Their recent investments include Cour Pharmaceuticals Development, Roche Venture Fund, Bristol-Myers Squibb, Alpha Wave Ventures, Anokion. The highest investment round they participated in was $3.0B. Among their most notable exits are Cour Pharmaceuticals Development and Roche Venture Fund. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Employees
N/A
Investment portfolio
Pfizer Breakthrough Growth Initiative has made 9 investments. Their most recent investment was on Jan 30, 2024, when Cour Pharmaceuticals Development raised $105.0M.
Pfizer Breakthrough Growth Initiative has made 2 diversity investments. Their most recent diversity investment was on Nov 18, 2021, when Cardiff Oncology raised $15.0M.
investments
9
Diversity investments
2
Lead investments
8
Number of exits
6
Investments
9
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Jun 16, 2022 | - | - | 25.0M |
| Jul 13, 2022 | AgomAb Therapeutics | Biotechnology | 38.5M |
| Oct 18, 2022 | Anokion | Biotechnology | 35.0M |
| Jan 30, 2024 | Cour Pharmaceuticals Development | Biotechnology | 105.0M |
Exits
6
Funding Timeline
Funding rounds
9
Investors
0
Funds
0
Funding Rounds
9
Pfizer Breakthrough Growth Initiative has raised 9 rounds. Their latest funding was raised on Jan 30, 2024 from a Series A - Cour Pharmaceuticals Development round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Jun 16, 2022 | Post-IPO Equity - Akero Therapeutics | - | 25.0M | - |
| Jul 13, 2022 | Series B - AgomAb Therapeutics | - | 38.5M | - |
| Oct 18, 2022 | Venture Round - Anokion | - | 35.0M | - |
| Jan 30, 2024 | Series A - Cour Pharmaceuticals Development | - | 105.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
N/A
Recent Activity
There is no recent news or activity for this profile.